Renal toxicity caused by brand-name versus generic cisplatin: A comparative analysis

Japanese Journal of Clinical Oncology

Volumn 43, Issue 4, 2013, Pages 390-395

  Niho, Seiji ^a   Yamanaka, Takeharu ^a   Umemura, Shigeki ^a   Matsumoto, Shingo ^a   Yoh, Kiyotaka ^a   Goto, Koichi ^a   Ohmatsu, Hironobu ^a   Ohe, Yuichiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Brand name; Cisplatin; Generic; Renal toxicity

Indexed keywords

CISPLATIN; CREATININE; GEMCITABINE; GENERIC DRUG; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; DRUG FORMULATION; FEMALE; FUNCTIONAL STATUS; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; OUTCOME ASSESSMENT; PERFORMANCE; RETROSPECTIVE STUDY; SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; CREATININE; DRUGS, GENERIC; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; THORACIC NEOPLASMS;

EID: 84875791060     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt020     Document Type: Article

References (14)

1. Reed E. Cisplatin and its analogs. In: DeVita VT, Lawrence TS, Rosenberg SA, editors. Cancer: Principles & Practice of Oncology. 8th edn. Philadelphia: Wolters Kluwer Lippincott Williams & Wilkins 2008;419-26.
2. Horwich A, Sleijfer DT, Fossa SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15:1844-52.
3. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995;13:1493-500.
4. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-57.
5. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-9. 6. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518.
6. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB. Mechanisms of cisplatin nephrotoxicity. Toxins (Basel) 2010;2:2490-518.
7. Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 2012;7(Suppl. 1):57-67.
8. Sekine I, Kubota K, Tamura Y, et al. Innovator and generic cisplatin formulations: comparison of renal toxicity. Cancer Sci 2011;102:162- 5.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
10. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000. Ann Intern Med 2005;142: 891-7.
11. Bodnar L, Wcislo G, Gasowska-Bodnar A, et al. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer 2008;44:2608-14.
12. Willox JC, McAllister EJ, Sangster G, Kaye SB. Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 1986;54:19-23.
13. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 2007;18:317-23.
14. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98.